INHIBITION OF THE FACTOR XA (WITH RIVAROXABAN) SLOW DOWN PROGRESSION, PREVENTS COMPLICATION AND DECREASE MORTALITY IN CORONARY HEART DISEASE
https://doi.org/10.15829/1560-4071-2018-3-65-70
Abstract
A review presented, of the novel scientific data, mostly the results of large clinical trials, witnessing on clinical efficacy and safety of rivaroxaban — the anticoagulant, selective blocker of Xa factor — in treatment of acute and chronic coronary heart disease. The mechanisms explained, of the drug influence on atherothrombosis, especially the specifics of dosages and its combination with other antithrombotic drugs in various clinical situations.
About the Author
V. N. Khirmanov
A. M. Nikiforov Russian Center of Urgent and Radiation Medicine of the EMERCOM.
Russian Federation
Saint-Petersburg.
Russian Federation
Saint-Petersburg.
References
1. Bhatt DL, Eagle KA, Ohman EM, et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA. 2010; 304: 1350-07. DOI: 10.1001/jama.2010.1322.
2. Sahlén A, Varenhorst C, Lagerqvist B, et al. Outcomes in patients treated with ticagrelor or clopidogrel after acute myocardial infarction: experiences from SWEDEHEART registry. Eur Heart J. 2016; 37: 3335-42. DOI: 10.1093/eurheartj/ehw284.
3. Kubo T, Maehara A, Mintz GS, et al. The dynamic nature of coronary artery lesion morphology assessed by serial virtual histology intravascular ultrasound tissue characterization. J Am Coll Cardiol. 2010; 55: 1590-97. DOI: 10.1016/j.jacc.2009.07.078.
4. Rittersma SZ, van der Wal AC, et al. Plaque instability frequently occurs days or weeks before occlusive coronary thrombosis: a pathological thrombectomy study in primary percutaneous coronary intervention. Circulation. 2005; 111: 1160-65. DOI: 10.1161/01. cir.0000157141.00778. ac.
5. Grainger DJ, McWilliam NA, Baglin TP, et al. Suppressing thrombin generation is compatible with the development of atherosclerosis in mice. Thromb Res. 2001; 102: 71-80. DOI: 10.1016/S0049-3848(01)00211-0.
6. Borissoff JI., Spronk HM, Heeneman S, et al. Is thrombin a key player in the ‘coagulationatherogenesis’ maze? Cardiovasc Res. 2009; 82: 392-403. DOI: 10.1093/cvr/cvp066.
7. Lee IO, Kratz MT, Schirmer SH, et al. The effects of direct thrombin inhibition with dabigatran on plaque formation and endothelial function in apolipoprotein E-deficient mice. J Pharmacol Exp Ther. 2012; 343: 253-57.
8. Kalz J, ten Cate H, Spronk HM. Thrombin generation and atherosclerosis. J Thromb Thrombolysis. 2014; 37: 45-55. DOI: 10.1124/jpet.112.194837.
9. Spronk HM, Borissoff JI, ten Cate H. New insights into modulation of thrombin formation. Curr Atheroscler Rep. 2013; 15: 363. DOI: 10.1124/jpet.112.194837.
10. Ten Cate H, Hemker HC. Thrombin Generation and Atherothrombosis: What Does the Evidence Indicate? J Am Heart Assoc. 2016; 5. pii: e003553. DOI: 10.1161/JAHA.116.003553.
11. Valente-Acosta B, Baños-González MA, Peña-Duque MA, et al. Association between Stable Coronary Artery Disease and In Vivo Thrombin Generation. Cardiol Res Pract. 2016; 2016: 5149825. DOI: 10.1155/2016/5149825/.
12. Al Dieri R, Ten Cate-Hoek A, Bloemen S, et al. Procoagulant effect of vitamin K antagonists? J Thromb Haemost. 2011; 9: 2511-12. DOI: 10.1111/j.1538-7836.2011.04527.x.
13. Schurgers LJ, Spronk HM. Differential cellular effects of old and new oral anticoagulants: consequences to the genesis and progression of atherosclerosis. Thromb Haemost. 2014; 112: 909-17. DOI: 10.1160/TH14-03-0268.
14. Li X, Vink A, Niessen HW, Kers J, et al. Total burden of intraplaque hemorrhage in coronary arteries relates to the use of coumarin-type anticoagulants but not platelet aggregation inhibitors. Virchows Arch. 2014; 465: 723-29. DOI: 10.1007/s00428-014-1654-y.
15. Anand SS, Yusuf S. Oral anticoagulants in patients with coronary artery disease. J Am Coll Cardiol. 2003; 41: 62S-69S. DOI: 10.1016/S0735-1097(02)02776-6.
16. Dewilde WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013; 381: 1107-15. DOI: 10.1016/S0140-6736(12)62177-1.
17. Khirmanov VN. New Anticoagulants in the Treatment of Patients With Recent Acute Coronary Syndrome. Place of Rivaroxaban. Kardiologiia.2015; 55 (6): 98-104. (In Russ) Хирманов В. Н. Новые антикоагулянты в лечении больных, недавно перенесших острый коронарный синдром. Место ривароксабана. Кардиология, 2015, 55 (6): 98-104. PMID: 26625526.
18. Bavishi C, Koulova A, Bangalore S, et al. Evaluation of the efficacy and safety of dual antiplatelet therapy with or without warfarin in patients with a clinical indication for DAPT and chronic anticoagulation: A meta-analysis of observational studies. Catheter Cardiovasc Interv. 2016; 88: E12-22. DOI: 10.1002/ccd.26234.
19. Zhu W, Guo L, Liu F, et al. Efficacy and safety of triple versus dual antithrombotic therapy in atrial fibrillation and ischemic heart disease: a systematic review and meta-analysis. Oncotarget. 2017; 8: 81154-66. DOI: 10.18632/oncotarget.20870.
20. Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N. Engl. J. Med. 2012; 366 (1): 9-19. DOI: 10.1056/NEJMoa1112277.
21. Gibson CM, Chakrabarti AK, Mega J, et al. Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51. J Am Coll Cardiol. 2013; 62: 286-90. Doi: 10.1016/j.jacc.2013.03.041.
22. Mega JL, Braunwald E, Wiviott SD, et al. Comparison of the efficacy and safety of two rivaroxaban doses in acute coronary syndrome (from ATLAS ACS 2-TIMI 51). Am J Cardiol. 2013; 112: 472-78. DOI: 10.1016/j.amjcard.2013.04.011.
23. O‘Donoghue ML, Braunwald E, White HD, et al. Effect of darapladib on major coronary events after an acute coronary Syndrome: the SOLID-TIMI 52 randomized clinical trial. JAMA. 2014; 312: 1006-15. DOI: 10.1001/jama.2014.11061.
24. Steg PG, Bhatt DL, et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA. 2007; 297: 1197-206. Doi: 10.1001/jama.297.11.1197.
25. Salim Yusef, Introduction to vascular protection with Factor Xa inhibition. Presented at ESC 2017.
26. Bhatt DL, Steg PG, Ohman EM. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006; 295: 18089. DOI: 10.1001/jama.295.2.180.
27. Bosch J, Eikelboom JW, Connolly SJ, et al. Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial. Can J Cardiol. 2017; 33: 1027-35. DOI: 10.1016/j.cjca.2017.06.001.
28. Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med. 2017; 377: 1319-30. DOI: 10.1056/ NEJMoa1709118.
29. Anand SS, Bosch J, Eikelboom JW, et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, doubleblind, placebo-controlled trial. Lancet. 2017. pii: S0140-6736(17)32409-1. [Epub ahead of print]. DOI: 10.1016/S0140-6736(17)32409-1.
30. Kralev S, Schneider K, Lang S, et al. Incidence and severity of coronary artery disease in patients with atrial fibrillation undergoing first-time coronary angiography. PLoS One. 2011; 6: e24964. DOI: 10.1371/journal.pone.0024964.
31. Bhatt DL, Flather MD, Hacke W, et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol. 2007; 49: 1982-88. DOI: 10.1016/j.jacc.2007.03.025.
32. Morrow DA, Braunwald E, Bonaca MP, et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med. 2012; 366: 1404-13. DOI: 10.1056/NEJMoa1200933.
33. Bonaca MP, Bhatt DL, Cohen M, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015; 372: 1791-800. DOI: 10.1056/ NEJMoa1500857.
34. Chaikriangkrai K, Valderrabano M, Bala SK, et al. Prevalence and Implications of Subclinical Coronary Artery Disease in Patients With Atrial Fibrillation. Am J Cardiol. 2015; 116: 1219-23. DOI: 10.1016/j.amjcard.2015.07.041.
35. Lemesle G, Ducrocq G, Elbez Y, et al. Vitamin K antagonists with or without long-term antiplatelet therapy in outpatients with stable coronary artery disease and atrial fibrillation: Association with ischemic and bleeding events. Clin Cardiol. 2017; Jul 10. DOI: 10.1002/ clc.22750. [Epub ahead of print].
36. Fiedler KA, Maeng M, Mehilli J, et al. Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: the ISAR-TRIPLE trial. J Am Coll Cardiol. 2015; 65: 1619-29. DOI: 10.1016/j.jacc.2015.02.050.
Review
For citations:
Khirmanov V.N. INHIBITION OF THE FACTOR XA (WITH RIVAROXABAN) SLOW DOWN PROGRESSION, PREVENTS COMPLICATION AND DECREASE MORTALITY IN CORONARY HEART DISEASE. Russian Journal of Cardiology. 2018;(3):65-70. (In Russ.) https://doi.org/10.15829/1560-4071-2018-3-65-70
Views:
780
Email this article 